These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 1902055)

  • 1. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
    Pritchett EL; Wilkinson WE
    Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
    N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
    Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP
    J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encainide--an updated safety profile.
    Thomis JA
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():585-94. PubMed ID: 2125837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial.
    Coyle JD; Schaal SF
    DICP; 1989 Jun; 23(6):478-9. PubMed ID: 2500783
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardiac arrhythmia suppression trial (CAST).
    Ruskin JN
    N Engl J Med; 1989 Aug; 321(6):386-8. PubMed ID: 2501683
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fact and fiction--results of the cardiac arrhythmia suppression trial.
    Wyse DG
    Can J Cardiol; 1991; 7(1):51-4; discussion 55-8. PubMed ID: 1902755
    [No Abstract]   [Full Text] [Related]  

  • 15. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide and CAST.
    Lancet; 1989 Aug; 2(8661):481-2. PubMed ID: 2570188
    [No Abstract]   [Full Text] [Related]  

  • 19. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from the cardiac arrhythmia suppression trial.
    Garratt C; Ward DE; Camm AJ
    BMJ; 1989 Sep; 299(6703):805-6. PubMed ID: 2510839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.